The three REIMAGINE trials, published simultaneously in The Lancet Diabetes & Endocrinology (REIMAGINE 1 and 2) and The Lancet (REIMAGINE 3), each met their primary endpoints for A1C reduction and confirmed secondary endpoints for weight loss across diverse type 2 diabetes populations
Hossain A, Yamaguchi F, Matsuo T, et al
however, like all supplements, it carries some risks
Throughout this process, it is crucial to avoid unapproved compounded products or research chemicals. The FDA has warned about dosing errors and adverse events from compounded semaglutide and other non-approved GLP-1 formulations sold online
Arrae Health Is Proud To Partner With Oasis Psychiatry & Wellness to offer expanded psychiatry services for our patients and community.
Because Mounjaro has one more GLP-1 receptor agonist than semiglutide (Ozempic, Zepbound) it may be more effective